CDK4 and acute lymphoblastic leukemia: Indeed, Pikman et al. showed that the CDK4/6 inhibitor LEE001 (ribociclib) administered concomitantly or subsequently with methotrexate, mercaptopurine, doxorubicine, and L-asparaginase exerts an antagonistic effect in several T-ALL cell lines in vitro (Figure 3).